FindTrial
Sign In

A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCITE (CITARABINE LIPOSOMIALE INJECTON) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPOBLASTIC LEUKEMIA OR VERY RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR VERY AGGRESSIVE LYMPOMA

A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCITE (CITARABINE LIPOSOMIALE INJECTON) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPOBLASTIC LEUKEMIA OR VERY RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR VERY AGGRESSIVE LYMPOMA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004082-15-IT
Enrollment
Unknown
Registered
2007-07-19
Start date
2004-11-09
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CNS RELAPSE IN ADULT PATIENT'S WITH ACUTE LYPHOBLASTIC LEUKEMIA O VERY AGGRESSIVE LYMPHOMA MedDRA version: 6.1 Level: HLGT Classification code 10025322

Interventions

Trade Name: DEPOCYTE Pharmaceutical Form: Suspension for injection INN or Proposed INN: Cytarabine CAS Number: 147-94-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration numb

Sponsors

AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026